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Abstract 
The presence of monoamines and their cofactors (the pterins and vitamin B6 (pyridoxal 
phosphate)) in human cerebrospinal fluid (CSF) can be used as indicators of the 
biosynthesis and turnover of dopamine and serotonin in the brain. In addition, 
abnormalities in the CSF levels of these molecules are associated with various 
neurological diseases, including genetic diseases leading to dopamime and serotonin 
deficiency. Here we provide a set of quantitative high-performance liquid-
chromatography (HPLC) approaches to determine CSF levels of monoamines and their 
cofactors. This protocol describes step-by-step procedures for CSF sample preparation 
for analysis of the different molecules, HPLC calibration and analysis, and data 
quantification and interpretation. Unlike, plasma/tissue/blood samples, CSF requires 
minimal sample preparation: in this protocol, only the analysis of pyridoxal phosphate 
requires mixing with trichloroacetic acid to release the protein-bound vitamin, 
centrifugation, mixing the supernatant with phosphate buffer and sodium cyanide for 
derivatization in alkaline conditions. Monoamines are analysed by HPLC with 
coulometric electrochemical detection, pterins by HPLC with coupled coulometric 
electrochemical and fluorescence detection, and pyridoxal phosphate by HPLC with 
fluorescence detection. The quantification of all compounds is achieved by external 
calibration procedures and internal quality control and standards are analyzed each run. 
We anticipate that investigation of dopamine and serotonin disturbances will be 
facilitated by measurements of these compounds in human CSF and other biological 
samples. The estimated time for the different procedures primarily depends on the 
electrochemical detector stabilization. Overnight stabilization of this detector is advised, 
and after that step, preanalytical equilibration rarely exceeds 3 hours. 
 
KEYWORDS monoamine; pterin; pyridoxal-phosphate; coulometric electrochemical 
detection; fluorescence detection; cerebrospinal fluid; high-performance liquid-
chromatography; HPLC-ED; HPLC-FD; UHPLC; cerebrospinal fluid; serotonin; 
dopamine; homovanillic acid; 5-hydroxyindoleacetic acid; tetrahydrobiopterin; CSF 
EDITORIAL SUMMARY The levels of monoamines and their cofactors in 
cerebrospinal fluid are strong indicators for dopamine and serotonin biosynthesis and 
turnover. This protocol describes a set of HPLC-based approaches for the quantitative 
detection of these molecules. 
TWEET Detecting #monoamines and their cofactors in human cerebrospinal fluid 
using #HPLC 
 
COVER TEASER HPLC detection of monoamines and their cofactors.   
Please indicate up to four primary research articles where the protocol has been used 
and/or developed.  
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INTRODUCTION 
Monoamines, such as dopamine and serotonin, have fundamental roles in motor, 
perceptual, cognitive and emotional brain functions along with other functions, 
including vascular tone, temperature regulation, endocrine regulation, and swallowing1. 
The relevant pathways for their synthesis and disease-associated genetic defects are 
shown in Supplementary Figure 1 and Supplementary Table 1. Several genetic and 
environmental conditions have been shown to affect the metabolism of dopamine and 
serotonin or the cofactors that are essential for the proper biosynthesis of these 
monoamines (pterins and pyridoxal phosphate (PLP))1. Aromatic L-amino acid 
decarboxylase and tyrosine hydroxylase deficiencies are two relevant genetic diseases 
(see also Supplementary Figure 1 and Supplementary Table 1). The quantitative 
detection of monoamines and their cofactors in the cerebrospinal fluid (CSF) can be 
used as an indicator for dopamine and serotonin biosynthesis and turnover in the brain 
and is considered of important diagnostic marker for a number the conditions described 
above. The status of the dopamine and serotonin systems in the central nervous system 
can for instance be studied by measuring the levels of homovanillic acid (HVA) and 5-
hydroxyindoleacetic acid (5HIAA), respectively2,3. The CSF concentrations of these 
primary (and stable) end-metabolites provide insights into the biosynthesis and turnover 
of dopamine and serotonin. Screening for other dopamine and serotonin metabolites can 
be done in the same chromatogram and enables a deeper investigation of the 
monoamine status in a single analysis2,3. These metabolites are 3-orthomethyldopa (3-
OMD) and methoxyhydroxyphenylglycol (MHPG) for dopamine pathway and 5-
hydroxytryptophan (5HTP) for serotonin pathway (see Figure 1).In addition, 
quantitative assessment of the CSF concentrations of cofactors that are essential for 
monoamine synthesis can provide important diagnostic information. Pterins (neopterin, 
dihydrobiopterin (BH2), and tetrahydrobiopterin (BH4)) are, for example, useful 
biomarkers for the research of BH4 metabolism-associated genetic disorders. Neopterin 
analysis is a powerful tool for identifying inflammatory and immune conditions in the 
central nervous system4. Determining CSF PLP concentrations provides insights into 
the various genetic and environmental conditions that lead to a brain PLP deficiency5, 
which consequently affects dopamine and serotonin biosynthesis. In this protocol, we 
will describe several HPLC-based biochemical methods for the quantification of CSF 
concentrations of the aforementioned biomarkers (see Table 1). The monoamine 
quantification procedures specified here can also be adapted for the quantification of 
other monoamines for diagnostic and research purposes. In addition, this methodology 
can be used for the investigation of the neurotransmisson status both in animal and 
celular models, and for the analysis of plasma and urine samples.  
 
 
 
Overview of the procedures 
The first critical step towards studying the aforementioned compounds is the CSF 
sample collection procedure. For most of the diseases shown in Supplementary Table 
1, analyses of blood or urine sample are unreliable for brain dopamine and serotonin 
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status estimations. CSF collection should be performed by an expert clinician, and strict 
follow-up of the pre-analytical protocol is mandatory6,7.  
For the chromatographic separation of the biomarkers presented here, different HPLC 
methods are used: ion-pair HPLC is based on the modification of a reverse phase 
column to separate ionized compounds. Reverse phase HPLC allows the separation of 
compounds by hydrophobic interactions with the stationary phase of the column. With 
regards to detection, electrochemical detection (ED) is used to quantify redox active 
compounds by applying a potential and measuring the resulting current produced, which 
is proportional to the concentration. Fluorescence detection (FD) is used for the 
quantification of compounds with either native (pterins analysis) or derivatized 
fluorescent groups (pyridoxal phosphate (PLP) analysis). In fluorescence detection the 
compound is excited at one wavelength (excitation) and measured at another 
wavelength (emission) (see Table 2 for details).    
 
For the CSF monoamine quantification (option A, procedure section) ion-pair HPLC 
with coulometric electrochemical detection (HPLC-ED) is the gold standard because it 
enables a highly sensitive separation and quantification of these compounds2,7.  
 
For the CSF pterin analysis HPLC with fluorescence detection (HPLC-FD) is single 
approach for the rapid quantification of the oxidized pterins (neopterin, biopterin, 
primapterin and sepiapterin) as an estimation of the biosynthesis and metabolism of the 
active pterin (BH4). This procedure has previously been reported in detail3 and will not 
be included in this protocol. In-line HPLC-ED-FD (option B, procedure section), is also 
available for the quantification of total neopterin, BH4 and its precursor, BH2,
 and it will 
be detailed in this report3. This in-line method allows the simultaneous quantification of 
both electroactive (BH4) and fluorescence compounds (BH2 and neopterin). For the PLP 
analysis (option C, procedure section), HPLC-FD offers a single-high-sensitivity 
approach for the PLP quantification8,9. The results for each technique are reported as 
absolute values in the nmol/L range.  
 
 
Applications of the method 
The most common applications for the methods described here include  the diagnosis of 
primary genetic conditions that lead to neurotransmitter deficiencies and other severe 
early onset neurological diseases that can be associated with disturbances in brain 
dopamine and serotonin availability10,11. The procedures may also be suitable for the 
quantification of monoamines, such as dopamine, serotonin and related compounds, in 
experimental animal and cellular models after adequate sample extraction and 
purification steps, (acid precipitation on ice, centrifugation, and supernatant filtration) 
as previously reported12,13,14. Brain microdialysis procedures also allow the 
determination of monoamines and other molecules in interstitial tissue fluid15. 
Fukushima et al reported several works studying BH4 and its metabolites by HPLC with 
fluorescence detection in different rat tissues (pineal, liver, adrenal, brain and blood) 
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showing that the same methodology is also useful for human samples (blood and 
urine)11. 
Elution and quantification of other monoamines are expected to occur in the same 
chromatogram as the key monoamines metabolites of interest (Figure 1). For the pterins, 
applications beyond identification of primary genetic causes of BH4 deficiency may 
include studies of brain inflammatory/immune events by CSF neopterin quantification. 
An analysis of PLP can detect a suboptimal vitamin B6 status due to nutritional 
deficiencies, increased turnover, increased sequestration by chemical adducts, and other 
environmental and genetic conditions that promote its deficiency5,16,17.  
 
Comparison with other commonly employed methods 
The methods described here have routinely been used to investigate biogenic amines 
and pterins in the CSF. Ultra-high performance liquid chromatography–tandem mass 
spectrometry (UHPLC/MS-MS) methods are increasingly used in bioanalytical 
investigations due to their sensitivity, specificity and efficacy in different biological 
materials18. A targeted metabolomics approach is a noteworthy alternative to HPLC-
based strategies, and new developments towards future human diagnostic applications 
are expected. Kovac et al. developed a LC/MS method to assess 5-hydroxytryptamine, 
5HIAA, HVA, noradrenaline, adrenaline, dopamine, glutamate, γ-aminobutyric acid, 
3,4-dihydroxyphenylacetic acid, and histamine in the CSF of a rat model18. Santos-
Fandila et al. described an analysis of neurotransmitters, metabolites and derivatives in 
rat microdialysates by UHPLC-tandem mass spectrometry19. LC-MS/MS has also been 
used for pterin analyses and involves simultaneous detection of BH4, BH2 and biopterin 
in urine samples, cell extracts and the rat brain20,21,22. However, according to 
aforementioned authors, MS/MS detection is less sensitive than FD for pterin 
quantification. For PLP, an UHPLC-MS/MS approach has been published 23,24, which 
allows the identification of seven vitamin B6 vitamers in human CSF samples, though 
this procedure is not routinely used for PLP quantification in biological fluids. Recently, 
a simultaneous measurement of monoamine metabolites and, also 5-
methyltetrahdyrofolate, in CSF by HPLC-FD has been developed25. 
Taking together, the methodological information stated in this work may be very helpful 
for both clinical and basic research laboratories.  
 
Limitations 
Practical limitations in sample preparation are worth of consideration. First, sometimes 
the sample volume is not sufficient for doing all of the investigations required. 
Moreover, CSF contamination by blood after traumatic lumbar puncture may cause 
autoxidation of some compounds (such as monoamines26). Regarding CSF matrix 
effects, they are less important than those of blood or other tissues, and they have been 
reported mainly associated with mass spectrometry procedures. The main limitations of 
the present protocol are related to the HPLC-ED system. While HPLC-FD is robust and 
highly sensitive, HPLC-ED needs an optimum equilibration and preparation of the 
system and requires specifically trained operators and so may be relatively time-
consuming. These issues and other ones will be described in the present protocol. The 
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establishment of accurate reference values is mandatory for proper data interpretation. 
The CSF samples from “healthy” paediatric controls are needed, but these samples are 
difficult to collect outside the Hospital setting. Because there is a strong correlation 
between the monoamine, pterin and PLP levels and age, a large CSF sample size is 
required for the the establishment of reference values, since several intervals must be 
defined. We took advantage of the lumbar punctures collected in our Hospitals for viral 
and bacterial meningitis diagnoses. Once these diseases were ruled out, we used the 
remaining sample as control samples to determine biogenic amines, pterins and PLP.  
 
Level of expertise  
These analytical procedures can be performed by competent professionals. The most 
complicated procedure involves ED, and special training for those managing this 
detector is advisable. However, the critical step involves the data interpretation because 
a high degree of experience is required to identify the genetic conditions mentioned in 
Supplementary Table 1 and to interpret the numerous secondary neurotransmitter, 
pterin, and PLP disturbances. Therefore, the data interpretation should be performed 
within the context of the clinical information provided by expert clinician in the field. 
 
Experimental Design 
The optimization for the biogenic amine, pterin and PLP measurements is divided into 
two stages as follows: (1) pre-analytical factors (sample collection and storage protocol) 
and (2) analytical factors (optimization of the HPLC-ED and FD settings and data 
interpretation). 
 
Pre-analytical factors: CSF is the ideal biological sample for diagnosing most biogenic 
amine disorders. A protocolized lumbar puncture collection is required for a reliable 
analysis of the monoamines, pterins and PLP (Table 3). Because there is a rostrocaudal 
gradient (i.e., the concentration of some metabolites is higher in the final CSF fractions 
than in the initial fractions), it is important to compare a patient’s values to his own 
reference values, which are established using the same CSF fraction6,7. Because red 
blood cell lysis causes oxidation of amine metabolites, blood-contaminated samples 
must immediately be centrifuged, and the clear CSF supernatant must be transferred to a 
new tube. To measure neopterin, BH2 and BH4, the CSF sample must be protected from 
light and stored with stabilizing agents because the reduced forms are extremely light- 
and oxygen-sensitive3. Because CSF samples have less interfering compounds when 
compared with other biological matrixes, such as blood, plasma, tissue extracts or urine, 
no extensive purification or extraction procedures are required, and only single dilution 
and filtration steps are needed prior to HPLC analysis7. However, guard column and 
graphite filters have to be regularly replaced to assure a good analytical performance. 
Sample storage at –70ºC with protection from light is mandatory (Table 3).  
 
Analytical factors for monoamine quantification: HPLC-ED is the most commonly 
used procedure for monoamine quantification. This approach is based on ion-pair 
chromatography separation, with a mobile phase consisting of citrate-acetate buffer at 
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an acidic pH that is supplemented with an ion-pair agent (heptanosulfonic acid or 
equivalent)6,7. The ion-pair agent has an ionic head group and a non-polar tail. The non-
polar tail interacts strongly with the C18-column, while the ionic head group is 
projected into the mobile phase. This column modification generates an attraction 
between ion-pair agent and ionized compounds allowing chromatographic retention and 
elution. Critical separation conditions that can dramatically change a compound’s 
elution time include the pH value of the mobile phase and the ion pair agent27. The 
detection of monoamines is mediated by on coulometric electrochemical detection 
(ED). In this approach, the electrochemical detector is used to determine the current 
generated between two electrodes placed in the detection cell. These electrodes are the 
working electrode (E1), where the current is generated, and the auxiliary (E2, or 
counter) electrode, where the complementary electrolytic reaction takes place. The 
potential between the electrodes is held constant, resulting in the complete oxidation of 
the analysed compounds of interest. Another electrode called reference electrode, is 
used to keep the potential stable throughout the measurements. The appropriate ED 
settings are very important to achieve complete oxidation of the analyte. The 
appropriate potential for ED can be determined by measuring the oxidative current of 
the analyte (at a constant concentration) over a range of working electrode potentials. 
The plot of current generated vs. applied potential is called the hydrodynamic 
voltammogram. We advise collecting a hydrodynamic volammogram plot regularly for 
every compound since different variables may influence the results, including factors 
like the mobile phase composition, the type and age of electrodes used, the deterioration 
of the graphite filter with the time, and others28. The applied potential at +450 mV is 
normally enough for the proper electrochemical oxidation of monoamines. This 
oxidation results in a current that can be sensed by the detector and is directly 
proportional to the monoamine concentration. , An example of a hydrodynamic 
voltammogram is shown for 5HIAA and HVA in Figure 2. Ideally, the lowest current 
that produces the highest analytical response to the electrode should be chosen since this 
lead to a lower background signal. Regarding the composition of electrodes, we used 
porous graphite electrodes since they have a large surface area. This permits the eluent 
to flow through the electrodes and thereby maximizes the contact area with electroactive 
compounds, increasing the sensitivity of the analysis. Special precautions should be 
taken for ED cell stabilization, maintenance, and cleaning, which are described in ED 
equipment setup and Box 1.    
 
Analytical factors for pterin quantification: HPLC with in-line electrochemical and 
fluorescence detectors is the method of choice for measuring CSF neopterin, BH2 and 
BH4 in the same chromatogram as pterin3. Neopterin, BH2 and BH4 are separated using 
reverse-phase HPLC. BH4 is measured by ED, where it is oxidized by electrode 1 (E1) 
to quinonoid dihydrobiopterin and reduced back to BH4 at electrode 2 (E2). The 
detector then uses the current generated by this reduction reaction to determine the 
concentration of BH4. Total neopterin (dihydroneopterin and neopterin) and BH2 can be 
measured in the same injection by fluorescence detection. A post-column oxidation of 
dihydroneopterin and BH2, using a conditioning cell at the optimal potential, oxidizes 
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dihydroneopterin to neopterin and BH2 to biopterin. Because dihydroneopterin and 
neopterin co-elute, they are detected as a single peak by the fluorimeter (excitation 360 
nm: emission 440 nm), which provides a total neopterin measurement. BH2 is detected 
and measured in the same chromatogram. A schematic representation of the ED cells is 
shown in Figure 3. 
 
Analytical factors for PLP quantification: CSF PLP quantification is performed by 
HPLC with fluorescence detection, as previously reported8,9. The mobile phase consists 
of a phosphate buffer. PLP is derivatized with sodium cyanide under alkaline 
conditions. The analytical details of these procedures are summarized in Table 2, and 
typical chromatograms of the different procedures are shown in Figure 4-6.   
 
Standards and controls: For protocol validation and application, we use different 
materials: standards (or calibrators) and internal and external quality control materials. 
For calibration purposes, the standard concentrations are close to those observed in 
human CSF samples. We use the standards to calibrate the procedure, to establish a 
relation between the concentration and the analytical response (area under the peak).  
The control materials are used to assess the matrix effects, since they are based on 
human biological matrixes. Since 2014, we have participated in an external quality 
control scheme (ERNDIM program) for monoamines and pterins. The ERNDIM control 
program consists of 8 different samples which are analysed throughout the year and the 
results of the 29 participants are compared. At the end of the program and according to 
fixed criteria the performance for accuracy, precision, linearity and recovery is graded 
for every participant.  
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MATERIALS 
REAGENTS 
!CAUTION Handle all toxic and flammable chemicals in a fume hood. 
!CAUTION All corrosive, flammable and poisonous reagents must be stored in 
appropriate laboratory storage systems as follows: 90-minute EN fire-resistant safety 
cabinet, 144470-1, Asecos, MPA Dresden, and a chemical cabinet for acids and alkalis, 
Asecos, MPA Dresden. 
CRITICAL Avoid using detergents to clean the glassware for HPLC-ED.  This will 
cause a substantial increase in the signal background. Glassware is rinsed with miliQ or 
ultrapure water and dried with methanol. Use glassware instead of plastic ware for the 
mobile phase and standard solution preparations. Transfer the solvents using glassware. 
Human CSF samples.  
CRITICAL All reagents should be freshly prepared for each use in volumetric 
glassware, unless suitable storage conditions are specified. When water is indicated, 
ultrapure water (18 MΩ) should be used. Mili-Q water treatment consists on UV lamp 
with two wavelengths to assure the degradation of organic molecules by photoxydation. 
Then, another ultrafiltration system (Quantum®) eliminates ionic and organic 
contaminants to very low trace concentrations. Finally, additional specific filters can be 
chosen according the needs of the laboratory (ultrapure water without particle matter, 
bacteria, lipopolisaccharide, nucleases and proteases).  
 
 
Cerebrospinal fluid (CSF): See Reagent Setup on information on sample collection 
and Table 3 for information on the required quantities. 
!CAUTION Our protocol was developed at two different institutions, The National 
Hospital for Neurology and Neurosurgery, United Kindom (UK) and Hospital Sant Joan 
de Déu , Spain. In the UK, the Royal College of Pathologist's guidelines (2012) that 
refer back to the Human Tissue Act, allow for residual anonymised patient material to 
be used for method performance assessment and quality control purposes. At Hospital 
Sant Joan de Déu, the Ehics Committee approved the use of residual and anonymised 
CSF samples for the same purposes. Users of the protocol should obtain appropriate 
institutional approval and conform to national regulations. 
!CAUTION For the collection of CSF into the clinical diagnostic workflow, informed 
consent was always collected as for other medical interventions in both institutions. All 
samples from the patients were obtained in accordance with the 2013 revised Helsinki 
Declaration of 1964. 
!CAUTION Adhere to all guidelines and regulations associated with the collection and 
use of human CSF. All personnel working with such samples should be informed of the 
risks associated with borne pathogens and be trained in the use of correct sample-
handling techniques. Some infectious meningoencephahylitis cases can mimic genetic 
diseases and may be unrecognized prior to the HPLC analysis. Use appropriate personal 
protective equipment. 
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Monoamine analysis 
 Ultrapure water (Type I), 18.2 MΩ·cm; Milli-Q® Integral ZRXQ003WW. 
 Methanol (HPLC grade, ≥99.8%; Merck KGaA, cat. No. 1060018). !CAUTION 
Methanol is toxic and highly flammable, and it should be handled in the fume hood. 
 Citric acid (ACS reagent, ≥99.5%; Sigma-Aldrich, cat. No. 251275). 
 Sodium acetate trihydrate (BioXtra, ≥99.0%; Sigma-Aldrich, cat.no. S-7670). 
 Ethylenediaminetetraacetic acid dipotassium salt dihydrate (≥ 98%; Sigma-Aldrich, 
cat. No. ED2P). 
 Ion pair agent: 1-Heptanesulfonic acid sodium salt (BioXtra, Sigma-Aldrich, cat. no. 
H8901).  
 
Monoamine Standards 
 L-3-O-Methyl-DOPA (3-OMD) (Powder, ≥98%; Sigma-Aldrich, cat. No. M4255). 
 4-Hydroxy-3-methoxyphenylglycol sulfate potassium salt (MHPG) (≥98%; Powder, 
Sigma-Aldrich, cat. no. H8759). 
 5-Hydroxy-L-tryptophan (5HTP) (>98% Powder, Sigma-Aldrich, cat. no. H9772). 
 5-Hydroxyindole-3-acetic acid (dicyclohexylammonium) salt (5HIAA) (Crystalline, 
≥98% (TLC); Sigma-Aldrich, cat. no. H2255). 
 Homovanillic acid (HVA) (Powder ≥98%; Sigma-Aldrich, cat. no. H1252).  
 Internal quality control. Special Assays Urine, SKML, cat.no. SAU-01.  
CRITICAL: Store all standards and controls at -70ºC. 
 
Pterin analysis 
 Ultrapure water (18 MΩ; Main Lab). 
 Sodium acetate AnalaR (VWR, cat. no. 27652.232). 
 Citric acid (BDH HiPersolv, cat. no. 153144M). 
 Ethylenediaminetetraacetic acid (EDTA) disodium salt (for electrophoresis and 
molecular biology, 99.0-101.0% (titration); Sigma-Aldrich, cat. no. E5134). 
 1,4-Dithioerythritol (DTE) (≥99.0%; Sigma-Aldrich, cat. no. D8255). 
 Diethylenetriaminepentaacetic Acid (DETAPAC) (≥99%; Sigma-Aldrich, cat. no. 
D6518). !CAUTION DETAPAC can cause respiratory problems, and it should be 
handled in the fume hood. 
 Methanol (HPLC grade) (VWR HiperSolv for HPLC, cat. no. 152506X). ! 
CAUTION Methanol is toxic and highly flammable, and it should be handled in the 
fume hood. 
 Sodium hydroxide, pellets (Sigma, cat. no. 221465).  
Pterin Standards 
 D-Neopterin (Sigma-Aldrich, cat. no. N3386). CRITICAL Store in the dark at -
70ºC. 
 (6R)-5,6,7,8-Tetrahydrobiopterin dihydrochloride (Sigma, cat. no. T4425) 
CRITICAL Store in the dark at -70ºC. 
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 7,8-Dihydro-l-biopterin (Sigma, cat. no. 37272). CRITICAL Store in the dark at 
-70ºC.  
 Internal quality control. This is generated by pooling the clear CSF samples from 
previous patients with no evidence of pterin disorders. Mix thoroughly, aliquot and 
immediately freeze in labelled Eppendorf tubes at –70˚C. 
 
Pyridoxal phosphate analysis 
 Ultrapure water (Type I), 18.2 MΩ·cm; Milli-Q® Integral ZRXQ003WW.  
 Trichloroacetic acid (ACS grade, ≥99.5%; Merck KGaA, cat. no. 100807). 
!CAUTION Trichloroacetic acid is corrosive and should be handled in the fume 
hood. 
 Potassium phosphate dibasic K2HPO4 (ACS reagent, ≥98%; Sigma-Aldrich, cat. no. 
P3786). 
 Sodium cyanide (ACS reagent, ≥95%; Sigma-Aldrich, cat. no. 205222). 
!CAUTION Sodium cyanide is corrosive with acute toxicity and a high health 
hazard (respiratory sensitization, mutagenicity and carcinogenicity) and should be 
handled in the fume hood. 
 Acetonitrile (HPLC grade ≥99%, Merck KGaA, cat. no. 100030). !CAUTION 
Acetonitrile is toxic and highly flammable and should be handled in the fume hood. 
 Orthophosphoric acid (ACS reagent, 85%; Merck KGaA, cat. no. 100573). 
!CAUTION Orthophosphoric acid is corrosive and should be handled in the fume 
hood. 
 Semicarbazide hydrochloride (≥95%; Merck KGaA, cat. no. 107722). 
 Potassium phosphate monobasic KH2PO4 (ACS grade, ≥99.0%; Sigma-Aldrich, cat. 
no. P5379).  
 
Pyridoxal phosphate Standards 
 Pyridoxal phosphate plasma/serum calibration standard, lyophilized, 5x1 mL; 
Chromasystems, Teknokroma, cat. no. 36005. 
 Pyridoxal phosphate internal quality control, lyophilized, 5x2 mL; Chromasystems, 
Teknokroma, cat. no. 0039. 
 
EQUIPMENT 
HPLC systems  
Two HPLC systems coupled to electrochemical and fluorescence detectors are used. 
Please refer to Table 2 for detailed information on the different systems. 
 
Monoamines and pyridoxal phosphate   
 HPLC binary pump (Waters, model 1525. Milford, MA 01757, USA).  
 Refrigerated autosampler injection system (Waters, model 717 plus). ▲CRITICAL 
We advise the use of a refrigerated autosampler, especially if a large number 
samples will be analysed. 
 In-line degasification system, AF 186001273, Waters. ▲CRITICAL If dissolved 
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gases reaches the ED or FD, HPLC pressure oscillations and high-noise background 
signals will appear (as described in Coulochem II. Operating Manual ESA Inc 
(USA, 1997)). 
 Interface module for equipment communication (SAT/IN, Waters). 
 Integration programme, Breeze (Version 3.0, Waters). 
 Monoamine column: Reverse-phase HPLC column, nucleosil C18 (octadecylsilane; 
ODS, 5-µm, 250 × 5 mm column) cat. no. 720041.46, Macherey-Nagel. Guard ODS 
column (Teknokroma cat. no. TR-C-160-1).  
 Pyridoxal phosphate column: HPLC column C8 (octylsilane; OS, 5-µm, 250 × 4.6 
mm column) Symmetry shic, cat. no. WAT 200661. Guard C8 column 
(Teknokroma cat. no. TR-C-160-3).  
▲CRITICAL Columns are used only for the indicated applications. Average 
numer of samples analyzed with the same column were 650 for monoamines and 
1450 for PLP. 
 
Pterins 
 TSP (Thermo separation products) Spectra series P100 pump. 
 Jasco AS-2057 plus a refrigerated autosampler.   
 Kontron instruments DEG 103 degasser. 
 Jones chromatography column heater. 
 Azur data capture system, PC and software. 
 Columns. Reverse-phase HPLC column, C18 (octadecylsilane; ODS, 5 µm, 250 x 
4.6 mm column), ODS pre-column cartridge, Teknokroma cat. no. TR-015326.  
▲CRITICAL The column is used only for the indicated application. Average 
number of samples analyzed with the same column was 825. 
 
Common HPLC accessories  
 PEEK tubing 1/16, 3 m Teknokroma cat. no. 25067. ▲CRITICAL Due to the 
sensitivity of the chromatographic separation, the internal diameter of the tubing 
should be consistently maintained between the HPLC and the column and between 
the column and the ED and FD. 
 Reagent bottles with caps (250 mL, 500 mL, 1 L, and 5 L), blue PP screw cap and 
pouring ring; Duran laboratory. cat. no. Z305189, Z305197, and  Z305200. 
 
Electrochemical detector 
 Electrochemical detector Coulochem II; Hucoa-Erlöss. 
 Electrochemical detector cell; ESA model 5011 analytical cell and ESA model 5021 
conditioning cell. 
 In-line graphite filters (Thermofisher, cat. no. 70-0898) placed between the column 
and the ED cell. ▲CRITICAL This is necessary to remove electroactive impurities 
prior to ED. It should be regularly replaced.  
 
Fluorescence detector 
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 Pterins. Jasco model FP-920, intelligent fluorescence detector. 
 Pyridoxal phosphate. Fluorescence detector (Waters, model 2475 Multi-
fluorescence detector). 
 
Accessories for sample and mobile phase preparation 
 pH-meter GLP21, Crison. ▲CRITICAL Calibration of the pH meter by an external 
accredited company is needed. 
 Precision scale Mettler Toledo New Classic MF model 104S. ▲CRITICAL 
Calibration of the precision scale by an external accredited company is needed. 
 Freezer at -70°C, Nuaire, model NU6580E. 
 Refrigerated centrifuge, HERAEUS, Labofuge 400R. 
 Microcentrifuge, cat. no.. 175508, Nirco (for pterins and PLP sample preparation). 
 Magnetic stirrer with ceramic plate, H20 LBX, 20 L; Labbox, cat. no. STIH-020-
001. Stirrer bar; Labbox, cat. no. MAGC-020-005. 
 Ductless Fume Cabinet; Ascent Max; Inflow: 187 L/s or 0.40 mL/s ± 0.025. ESCO 
cat. no. ADC-6C1. !CAUTION Electrical Hazard. Wear appropriate chemical-
resistant protective attire. 
 Vacuum pump KNF lab. Laboport and solvent filtration unit, Teknokroma cat. no. 
K-953855-1047. 
 Automatic pipettes 10-100 µL, 20-200 µL and 100-1000 µL, Nichipet EX, Nichiryo. 
▲CRITICAL Pipette calibrations by an external accredited company are required.  
 Glassware. Flasks and bottles: 5, 4, 2, and 1 L  0.4; 500 mL  0.250; and 10 mL  
0.02; Graduated cylinders: 100  0.5 mL and 1000  5 mL. Labbox; Glass pipettes: 
5  0.045 mL and 2  0.015 mL, Daslab, Nirco.▲CRITICAL Glassware 
calibrations by an external accredited company are essential for the preparation of 
the calibration solutions.  
 3 mL polypropylene round bottom tube (11 x 55 mm) Daslab, Nirco cat. no. 
175594.  
 Filtering membrane filters: nylon, 0.45-µm pore size and 47-mm diameter, pk/50, 
Teknokroma cat. no. NY 504700, for mobile phase filtering. 4-mm syringe filter 
(for 2.5 mL plastic syringes, Ico Plus3, Novico Medica cat. no. N15649) with a 
hydrophilic PVDF membrane (0.22-µm pore size) (Millex-GV; Merck Millipore cat. 
no. SLGVR04NL) and 10kDa centrifugal filters (Nanosep 10K omega, Pall Life 
Sciences cat. no. OD010c34) for non-sterile filtration of the samples. 
 HPLC vials: a 1-mL amber glass shell vial with a polyethylene snap cap, Waters cat. 
no. 025053C. Vial insert: 150-µL glass insert with polymer feet, Agilent cat. no. 
5183-2088. 
 Heat cabinet, Conterm Poupinel; Selecta cat. no. 2000200 for PLP sample 
preparation. 
 
 
 
REAGENT SETUP   
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CSF Sample collection: An overview of the CSF samples we collect and the required 
volumes is summarized in Table 3. Additional biomarkers, such as amino acids, can be 
determined in the CSF samples, and it is important to utilize this advantage. CSF 
samples are collected in conventional plastic tubes (10-ml round-bottom polystyrene 
tube) without preservatives, except for the pterins. For the pterin analysis, the sample 
must be collected into a microcentrifuge tube that contains dithioerythritol (1 mg) and 
diethylenetriaminepentaacetic acid (1 mg) (antioxidants). The sample volume estimation 
by drop number is useful for the clinician in charge of the CSF collection because the 
liquid leaves the spine drop by drop. Critical factors for consideration when collecting 
CSF samples include the rostrocaudal gradient, time of sample collection, protection 
from light and blood contamination. Immediately after collection, tubes (particularly 
tubes 2 - 4) must be placed on dry ice and frozen immediately at – 70ºC in the dark. If 
CSF is contaminated with blood, centrifuge the CSF samples (1500 g x 10 minutes at 
4ºC), and store the clear supernatant. Patient CSF samples can be stored for at least 10 
years at -70°C. !CAUTION The lumbar puncture is an invasive procedure, and critical 
factors should be considered. 
 
Monoamine “Mobile phase (buffer acetate citrate)”. This buffer contains 0.1 M 
sodium acetate, 0.1 M citric acid, 1.2 mmol/L EDTA, 1.2 mmol/L 1-heptanosulphonic 
acid, and 75 mL methanol, and it is adjusted to pH = 4. Weigh 13.61  0.01 g of sodium 
acetate into a 1-L flask, and add water up to 1 L. Weigh 9.60  0.01 g of citric acid into 
a 500- mL flask, and fill the flask to 500 mL with water. Adjust the pH of the sodium 
acetate with the citric acid to pH = 4. Separately weigh 0.44  0.01 g of EDTA and 
0.242  0.01 g of 1-heptanosulphonic acid, and add them into a 1-L glass bottle with a 
stir bar. In this bottle, add 75 mL of methanol and mix with the acetate-citrate buffer 
(pH = 4) up to 1 L. Filter the mobile phase through a solvent filtration unit with a 0.45-
μm nylon membrane. CRITICAL This buffer should be freshly prepared on the day 
of the analysis. 
 
Monoamine “3-OMD Standard”: Stock solution (401 µM). Weigh 2.30  0.04 mg of 
3-OMD and dissolve in a 25-mL volumetric flask with water. This can be stored for up 
to one year  at -70°C. 
 
Monoamine “MHPG Standard”: Stock solution (546 µM). Weigh 3.10  0.04 mg of 
MHPG and dissolve in a 25-mL volumetric flask with water. This can be stored for up 
to one year at -70°C. 
 
Monoamine “5-HTP Standard”: Stock solution (270 µM). Weigh 11.01  0.04 mg of 
5-HTP and dissolve in a 200-mL volumetric flask with water. This can be stored for up 
to one year at -70°C. 
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Monoamine “5HIAA and HVA Standard”: Stock solution (247 µM 5HIAA; 241 µM 
HVA). Weigh 4.60  0.04 mg of 5HIAA and 2.20  0.04 mg of HVA, and dissolve both 
in a 50-mL volumetric flask with water. This can be stored for up to one year at -70ºC.  
 
Monoamine “Calibration working solution”: 40.1 nM 3-OMD, 54.6 nM MHPG, 27 
nM 5-HTP, 494 nM 5HIAA and 482 nM HVA. In a 100-mL volumetric flask, add 10 
µL of each 3-OMD, MHPG and 5-HTP stock solution and 200 µL of each 5HIAA and 
HVA stock solution. Add 120 µL of 37% HCL, and fill the volumetric flask up to 100 
mL with water. CRITICAL The working calibration solution should be freshly 
prepared.  
 
Monoamine “Internal quality control”: Add 5 mL water to the lyophilized 
commercial vial. Mix gently and incubate for 15 min at room temperature. It is analysed 
for every run to check for data accuracy and to accept or reject the results of the 
analysis. CRITICAL Store in separate aliquots (110 µL) at -70°C. It is stable until 
the commercial expiry date. 
 
Monoamine Neurotransmitter external quality control scheme (ERNDIM 
programme): Add 500 µL water to the lyophilized sample. Mix by vortexing. The 
sample is ready to analyse. This can be stored for up to one year at -70°C.For details of 
this external quality control scheme, visit (www.erndimqa.nl). It is blindly analysed 
eight times per year to validate the accuracy of the procedure. The results are available 
upon request. 
 
Monoamine HPLC system wash solution: Filter 500 mL of water with 7.5% methanol 
(vol/vol). This can be stored for up to 1 month at room temperature (20-25ºC).  
 
Monoamine HPLC injector wash solution: water with 10 % methanol (vol/vol). This 
can be stored for up to 1 month at room temparature. CRITICAL: The column and 
injector washing procedures for all methods must contain organic solvents to avoid 
contaminations during storage.  
 
Pterin “Mobile phase”: Dissolve 27.20  0.01 g of sodium acetate (final concentration 
50 nM), 4.20  0.01 g of citric acid (final concentration 5 mM), 80.00  0.04 mg of 
EDTA (final concentration 48 M), and 98.81  0.04 mg of DTE (final concentration 
160 M) in 1.5 L of ultrapure water in a 2-L beaker. Bring the volume to 4 L with water 
in a volumetric flask. Thoroughly mix and transfer the buffer into the 5-L reagent bottle. 
CRITICAL All reagents should be freshly prepared for use with volumetric 
glassware, unless suitable storage conditions are specified. When water is indicated, 
ultrapure water (18 MΩ) should be used. 
 
Pterin “BH4 Standard”(500 µM): In a 100- mL volumetric flask, add 100  0.1 mg of 
DTE and DETAPAC to 80 mL of water and sonicate for 5 minutes to ensure that the 
DETAPAC has completely dissolved. Dissolve 15.7  0.1 mg of BH4 and bring the final 
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volume to 100 mL with water. Then, mix on ice for 30 minutes with a stir bar and a 
magnetic stirrer (in the dark). CRITICAL The 0.5-mL aliquots should be transferred 
to Eppendorf tubes and immediately frozen at -70ºC. The aliquots can be stored for up 
to 1 year. 
 
Pterin “D-Neopterin Standard”(500 µM): Prepare a 10 M NaOH solution by 
dissolving 10.0  0.1 g of NaOH in 25 mL of water. Slowly add NaOH while cooling on 
ice. Dissolve 10 µL of 10 M NaOH and 12.70  0.04 mg of D-neopterin in 80 mL of 
water in a foil-wrapped volumetric flask. Bring the volume to 100 mL and mix on ice 
for 30 minutes using a magnetic stirrer (in the dark). CRITICAL The 0.5-mL 
aliquots should be transferred to Eppendorf tubes and immediately frozen at -70ºC. The 
frozen aliquots can be stored for up to 1 year. Due to their light and temperature 
sensitivities, the 500 µM stock solutions for BH4 and D-neopterin should be prepared in 
foil-wrapped volumetric flasks and stored on ice. 
 
Pterin “BH2 Standard”(500 µM): Dissolve 80 µL of 10 M NaOH and 11.96  0.04 
mg of BH2 in 80 mL of H2O in a foil-wrapped volumetric flask. Bring the volume to 
100 mL with water and mix for 30 min on ice using a magnetic stirrer (in the dark). 
CRITICAL The 0.5-mL aliquots should be transferred to Eppendorf tubes and 
immediately frozen at -70ºC. The aliquots can be stored for up to one year. 
 
Pterin “Standard diluent”: Dissolve 25  0.04 mg of DTE and 2.5  0.04 mg of 
DETAPAC in 25 mL of water. Sonicate for 5 minutes to ensure DETAPAC dissolution. 
This can be stored for up to one year -70°C. 
 
 
Pterin “Working standard”: Pour approximately 8 mL of the standard diluent into a 
10-mL volumetric flask. Add 100 µL of each BH4, BH2 and neopterin stock standard, 
and bring the volume to 10 mL with the standard diluent. Thoroughly mix by inversion. 
Fill another 10-mL volumetric flask with approximately 8 mL of the standard diluent, 
and add 100 µL of the first stock standard dilution. Bring the volume to 10 mL, and 
thoroughly mix by inversion. CRITICAL A single working standard solution that 
contains 50 nM neopterin, BH2 and BH4, should be freshly prepared each day. The 
solution is stable throughout the day if stored in the dark on ice. 
 
Pterin “external quality control scheme (ERNDIM programme)”: Add 1 mL of 
water to the lyophilized sample. Mix by vortexing. The sample is ready to analyse. This 
can be stored for up to one year at -70°C.For details regarding this external quality 
control scheme, visit (www.erndimqa.nl). It is blindly analysed eight times per year to 
validate the accuracy of the procedure. The results are available upon request.  
 
Pterin “HPLC system wash solution”: water and 50 % methanol/water solution 
(vol/vol). This can be stored for up to one month at room temperature. 
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Pterin “HPLC injector wash solution”: water with 10 % methanol (vol/vol). This can 
be stored for up one month at room tempearture. 
 
Pyridoxal phosphate “Mobile phase”: 50 mM potassium dihydrogen phosphate 
(KH2PO4) with 75 mM semicarbazide. Weigh 6.80  0.01 g of KH2PO and 8.36  0.01 
g of semicarbazide into a 1-L flask, and add miliQ water up to 1 L (pH = 2.85).  Filter 
the mobile phase through a solvent filtration unit with a 0.45-μm nylon membrane.  
CRITICAL Prepare as needed. The mobile phase acidic pH is required for 
chromatographic separation, but it may decrease the FL signal. 
 
Pyridoxal phosphate “Trichloroacetic acid (10%)”: Weigh 10  0.01 g in a 100-mL 
flask, and add milliQ water. Store between 4-8ºC. The solution is stable for 6 months. 
 
Pyridoxal phosphate “Dipotassium hydrogen phosphate (3.3 M)”: Weigh 14.37  
0.04 mg of K2HPO4 in a 25-mL flask, and add milliQ water. Store between 4-8ºC. The 
solution is stable for 1 month. 
 
Pyridoxal phosphate “Sodium cyanide (0.04 M)”: Weigh 64.1  0.04 mg of sodium 
cyanide in a 25-mL flask, and add milliQ water. Store between 4-8ºC. The solution is 
stable for 1 month. ! CAUTION Sodium cyanide is extremely poisonous and should be 
handled in the fume hood with protective clothing and glasses. 
 
Pyridoxal phosphate “Orthophosphoric acid (2.86 M)”: Pipette 4.08 mL of 85% 
orthophosphoric acid (vol/vol) into a 25-mL flask, and add milliQ water. Store between 
4 and 8ºC. The solution is stable for 6 months. 
 
Pyridoxal phosphate “PLP Standard”: Add 1 mL milliQ water to the lyophilized 
commercial vial. Mix gently and incubate for 10-15 min at room temperature. Swirl the 
vial to completely dissolve its contents. This can be stored for up to 3 months at -20ºC  
 
Pyridoxal phosphate “PLP internal quality control”: A lyophilized commercial PLP 
control is available. Add 2 mL of distilled water into the vial. Gently mix and incubate 
for 10-15 min at room temperature. Swirl the vial to completely dissolve its contents. 
This can be stored for up to 3months at -20°C. 
 
Pyridoxal phosphate “HPLC system wash solution”: milliQ water with 10% 
acetonitrile (vol/vol). This can be stored for up to one month at room temparature. 
 
EQUIPMENT SETUP  
HPLC setup and maintenance The main details of the equipment description and 
setup are summarized in Table 2. HPLC with the ED and FD equipment setup should 
be performed by the user according to the manufacturer’s instructions.  
Detailed initial setup and maintenance procedures are provided by the manufacturer for 
the HPLC and ED/FD systems. The most critical details, which involve maintenance 
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and troubleshooting of the ED and FD are detailed in Table 4. Box 1 provides 
information for Electrochemical cell cleaning procedure.  
CRITICAL. The samples and freshly prepared mobile phases must be filtered (i.e., 
free of particulate matter). Check that columns are stable with regards the mobile phase 
and the overall system is clean. The in-line graphite filters should be placed before the 
ED cell. Flush the cells with ultrapure water and methanol when the system is shut 
down. The tubing end must be capped to avoid drying the ED cell.  
 
 
 
PROCEDURES 
1. This protocol describes the procedures for characterization of monoamines 
(Option A), Pterins (Option B), and Pyridoxal phosphate (Option C) levels from 
human CSF. Each section contains instructions for the preparation of standards, controls 
and samples, together with specific instructions for HPLC-setup and data-acquisition for 
each compound. 
A) Monoamine analysis TIMING 40 min for Standard, control and sample 
preparation,  3 hours for HPLC-ED setup and 35 min for data acquisition and 
analysis 
i. Standard, control, and sample preparation (Steps i-vii): Take the monoamine 
calibration stock solution, the internal quality control and CSF samples (see 
Reagent Setup) from the -70 ºC storage, and thaw the samples at room 
temperature. CRITICAL STEP The CSF samples, calibration solution and 
internal controls should be processed in the same way in all subsequent steps. 
ii. Prepare the calibration working solution as described in the Reagent Setup. 
iii. Thaw an internal quality control aliquote and dilute it 1:100 (vol/vol) in miliQ 
water: prepare 1:100 dilution by mixing 20 µL of internal quality control with 
1980 µL of miliQ water Prepare the external quality control (see Reagent Setup) 
according to ERNIDM schedule, 8 times per year)  
iv. Process the previously prepared CSF samples, calibration solution and internal 
and external controls by diluting the samples 1:2 (vol/vol) mixing 125 µL of 
sample with 125 µL of chromatographic mobile phase. CRITICAL STEP: 
For the ED, dilution with the mobile phase is required to reduce the sample 
matrix effects. 
v. Centrifuge the samples at 1500 x g for 10 min at 4ºC.  
vi. Filter the samples through 0.22-µm nylon filters to remove major contaminants 
and impurities.  
vii. Aliquot 200 µL of each sample into chromatographic labeled vials and put them 
in the rack.   
 
viii. HPLC-ED setup (Steps viii-xviii): Before running the standard, controls and 
CSF samples, the user has to connect the HPLC circuit. First, connect the 
graphite in-line filter before the ED cell. (see problem and solution in Table 4, 
TROUBLESHOOTING).  
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CRITICAL STEP The acquisition software (Breeze) should be operated by 
the user according to the manufacturer’s instructions (Waters).   
CRITICAL STEP Ensure not to overtighten the graphite filter, since it can 
become scratched if overtightened, thereby damaging the ED cell (Table 4, 
TROUBLESHOOTING).  
ix. Connect the mobile phase to the HPLC and purge all lines. CRITICAL 
STEP Before connecting the column, confirm that all incompatible solvents 
from the previous sample runs have been fully displaced.  
x. Place the column.  Columns are used only for the indicated applications (Table 
4, TROUBLESHOOTING).  
xi. Check for fluid leaks before equilibrating the system (Table 4, 
TROUBLESHOOTING). 
xii. Turn on the computer, and load the Breeze programme to capture and process 
the data from the ED. 
xiii. Transfer the inlet line to the mobile phase. 
xiv. Purge the pump with the mobile phase for 5 minutes using the Breeze 
programme (Table 4, TROUBLESHOOTING) . 
xv. Purge the injector and the detector with the mobile phase for 10 minutes using  
the Breeze programme. 
xvi. Equilibrate the system at 1.3 mL/min for at least 2 hours CRITICAL STEP 
The flow rate can be reduced to 0.3 mL/min if the system is allowed to run 
overnight. However, it is usually necessary to stabilize the system for at least 1 
hour after the flow rate is restored to 1.3 mL/min the following day. 
xvii. During the equilibration stage, programme the electrode parameters (E1 = +50 
mV; E2 = +450 mV, R2 = 200 nA) on the ED. Allow equilibration to proceed 
for at least 1 hour until the cell signal is stabilized (i.e., baseline signal is below 
500 nA) (Table 4, TROUBLESHOOTING) . 
xviii. Programme the autosampler in the Breeze programme to inject 30 µL of each 
sample from its position in the rack and set the time for 30 minutes.  Upload the 
monoamine method stored in the Breeze program. ED autozero function is 
applied after each sample analysis.  
xix. Data acquisition (Steps xix-xxi): To run the sample, click the “run sample" icon 
in the Breeze programme. The data capture will begin once an injection signal 
has been received from the autosampler. 
xx.  Check the standard and internal quality control. If they are well-separated and 
the values of calibration working solution (see Reagent Setup step, monoamine 
“calibration working solution”) and internal quality control (according to SKML 
commercial sheet) are within the assigned limits (usually within two standard 
deviations of the assay mean), the CSF samples can be run. Review the 
chromatograms and calculate the concentrations using the Breeze program. To 
calculate the results, load the chromatogram file and integrate the peaks of 
interest. If no CSF samples have to be reinjected, the ED can be turned off. 
xxi. Wash the system with 1 mL/min 7.5% (vol/vol) methanol (the same percentage 
as the mobile phase) for 2 hours.  
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B) Pterin ● TIMING 40 min for Standard, control and sample preparation, 3 
hours for HPLC-ED-FD setup and 25 min for data acquisition and analysis.  
i. Standard, control and sample preparation (Steps i-ii): Take the pterin 
calibration stock solution, the internal quality control, or CSF samples (see 
Reagent Setup) from the -70 ºC storage. Thaw at room temperature and 
thoroughly mix. Keep at 2 – 8°C in the dark until the analysis.  
CRITICAL STEP The CSF samples, calibration solution and internal 
controls should be equally processed in all subsequent steps. It is not strictly 
necessary to filter samples for the pterins method. However, some samples do 
require filtering (high protein or coloured CSFs). Filter CSF samples through 
10kDa centrifugal filters to remove major contaminants and impurities. 
ii. Aliquot 200 µL into amber capped, labelled autosampler vials and position them 
in the rack 
iii. HPLC-ED-FD setup (Steps iii-xii):  Before running the standard, controls and 
CSF samples, the user has to connect the HPLC circuit. First, connect the 
graphite in-line filter before the ED cell Table 4, TROUBLESHOOTING).  
CRITICAL STEP The acquisition software should be operated by the user 
according to the manufacturer’s instructions. Refer to the equipment setup 
procedures. 
CRITICAL STEP Ensure not to overtighten the graphite filter, since it can 
become scratched if overtightened, thereby damaging the ED cell.  The guard 
cell is placed after the ED and before the fluorescence detector.  
iv. Connect the mobile phase to the HPLC and purge all lines. CRITICAL STEP 
Before connecting the column, confirm that all incompatible solvents from the 
previous sample runs have been fully displaced. 
v. Place the column.  Columns are used only for the indicated applications (Table 
4, TROUBLESHOOTING) . 
vi. Check for fluid leaks before equilibrating the system (Table 4, 
TROUBLESHOOTING). 
vii. Purge the pump and ash the system with 50% methanol at a flow rate of 1 
mL/min for 2-3 hours (Table 4, TROUBLESHOOTING). CRITICAL 
STEP Because there is no methanol in the mobile phase, it is necessary to wash 
the system again with ultrapure water at 1 mL/min for 2-3 hours. 
viii. Transfer the inlet line to the mobile phase and allow the system to equilibrate at 
1.3 mL/min for at least 2 hours. CRITICAL STEP The flow rate can be 
reduced to 0.3 mL/min if the system is allowed to run overnight. However, it is 
usually necessary to stabilize the system for at least 1 hour after the flow rate is 
restored to 1.3 mL/min the following day. 
ix. After 30 min, turn on the ED and fluorescence detector. Programme the 
electrode parameters and wavelengths (Table 2).   
x. Check the optimal potentials from the previous run, and check the 
voltammograms to ensure that the optimal potentials are used for the analysis. 
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E1 should be adjusted so that the current is +0.5uA and E2 should be adjusted so 
that the current is -0.05uA – these currents give the optimal peak area for 
tetrahydrobiopterin. The voltages applied may vary but usually are: E1=+200 
mV; E2 = -500 mV; conditioning cell = +1100 mV (Table 2).  Measure the area 
of the peak. Modify the potentials of electrodes E1 and E2 as appropriate and 
repeat until the necessary potential/current is established for the maximum peak 
area. The peak area for the tetrahydrobiopterin standard should be consistent 
between runs (Table 4, TROUBLESHOOTING) . 
CRITICAL STEP Ensure that the green light is functioning for the cell’s 
in/out and run/stop keys, and leave the ED to equilibrate for at least 1 hour. 
xi. Turn on the computer and load Azur Data Capture to capture and process the 
data from the electrochemical and fluorescence detectors.  
xii. Programme the autosampler to inject 50 µL of the sample, control or standard 
onto the HPLC and set the run time to 20 minutes. Upload the pterins method 
stored in Azur program. ED autozero function is applied after each sample 
analysis. 
xiii. Data acquisition (Steps xiii-xv): To run the sample, click the “run sample” icon. 
The data capture will begin once an injection signal has been received from the 
autosampler.  
xiv. Check the standard and internal quality control. If they are well-separated and 
the values of calibration working solution (see Reagent Setup step) and quality 
control are correct, run the CSF samples. Review the chromatograms and 
calculate the concentrations using the Azur program. To calculate the results, 
load the chromatogram file and integrate the peaks of interest. If any CSF 
sample has not to be reinjected, turn off the ED and fluorescence detector. 
xv. Wash the system with ultrapure water at a flow rate of 1 mL/min for at least 1-2 
hours. Wash with 50% methanol/water (vol/vol) at a flow rate of 1 mL/min for 2 
hours or overnight. 
 
 
C) Pyridoxal phosphate analysis ● TIMING 40 min for Standard, control and 
sample preparation,  2 hours for HPLC-FD setup and  30min for data acquisition 
and analysis 
i. Standard, control and sample preparation (Steps i-vii): Take the PLP 
calibration stock solution, the internal quality control, and CSF samples (see 
Reagent Setup) from the -70 ºC storage, and thaw them at room temperature. 
CRITICAL STEP The CSF samples, calibration solution and internal 
controls should be equally processed in all subsequent steps. 
ii. Pipette 125 µL of each sample and 125 µL of 10% TCA into an Eppendorf vial, 
and mix by vortexing. Incubate at 50ºC in the dark for 5 min to completely 
release the protein-bound vitamin. 
iii. Centrifuge at 12.000 x g (10 min, 4ºC).  
iv. Pipette 200 µL of the resulting supernatant into an Eppendorf vial. Add 70 µL of 
3.3 M K2HPO4 and 20 µL of 0.04 M sodium cyanide in the chromatographic 
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vial to the supernatant and mix by vortexing (pH=7.4). Incubate at 50ºC in the 
dark for 25 min. CRITICAL STEP. In alkaline conditions, sodium cyanide 
oxidizes PLP to pyridoxic-5-phosphate, which can be measured by fluorescence 
detection. 
v. Add 25 µL of 2.86 M orthophosphoric acid to the samples to achieve an acidic 
medium (pH 2-4).  
vi. Filter the samples through 0.22-µm nylon filters to remove major contaminants 
and impurities. !CAUTION Cyanide/orthophosphoric acid can create toxic 
hydrogen cyanide and samples must be prepared and capped in the fume hood. 
vii. Transfer the filtered samples to chromatographic vials. The samples are now 
ready to inject.  
viii. HPLC-FD setup (Steps viii-xvii): Before running the standard, controls and 
CSF samples, the user has to connect the HPLC circuit. First, connect the FD to 
the system.  
CRITICAL STEP The acquisition software (Breeze) should be operated by 
the user according to the manufacturer’s instructions (Waters).  
ix. Connect the mobile phase to the HPLC and purge all lines. CRITICAL 
STEP Before connecting the column, confirm that all incompatible solvents 
from the previous sample runs have been fully displaced.  
x. Place the column. Columns are used only for the indicated applications.  
xi. Check for fluid leaks before equilibrating the system. 
xii. Turn on the computer, and load the Breeze programme to capture and process 
the data from the fluorescence detector.  
xiii. Purge the pump with the mobile phase for 5 minutes using Breeze programme. 
xiv. Purge the injector and the detector with the mobile phase for 10 minutes using 
Breeze programme. 
xv. Equilibrate the system at 1.5 mL/min for at least 30 min with the mobile phase.  
xvi. During the equilibration turn on the fluorescence detector and check that the 
signal is stable. The typical signal value should be close to zero (-0.06 – 0.03 FD 
signal) (Table 4, TROUBLESHOOTING) . 
xvii. Program the autosampler to inject 50 µL of each sample and set the time for 25 
minutes.  Upload the PLP method stored in the Breeze program. FD autozero 
function is applied after each sample analysis. 
xviii. Data acquisition and analysis (Steps xviii-xx): To run sample, click the “run 
sample” icon. The data capture will begin once an injection signal has been 
received from the autosampler.  
xix. Check the standard and internal quality control. If they are well-separated and 
the values of PLP calibration and internal quality control (according to 
Teknokroma commercial sheet) are within the assigned limits (usually within 
two standard deviations of the assay mean), the CSF samples can be run. Review 
the chromatograms and calculate the concentrations using the Breeze program. 
To calculate the results, load the chromatogram file and integrate the peaks of 
interest.  If no CSF samples have to be reinjected, the FD can be turned off. 
xx. Wash the system with ultrapure water/acetonitrile 90/10 (vol/vol), for 1 hour. 
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● TIMING 
Option A: Monoamine analysis 
Steps i-vii: Standard, control and sample preparation. 40 min. 
Steps viii-xviii: HPLC-ED setup: 3 hours (1 hour to prepare the HPLC system and 2 
hours to equilibrate the system). Overnight equilibration is advisable (flow rate 0.3 
mL/min). The next day, restore the flow rate to 1.3 mL/min at least one hour to stabilize 
the HPLC system.  
Steps xix-xxi: Data acquisition and analysis: 35 min per sample: 30 min for running the 
sample and 5 min for chromatographic data analysis. 
 
Option B: Pterin analysis 
Steps i-ii: Standard, control and sample preparation. 40 min. 
Steps iii-xii: HPLC-ED-FD setup. 3 hours (1 hour to prepare the HPLC system and 2 
hours to equilibrate the system). Overnight equilibration is advisable (flow rate 0.3 
mL/min). The next day, restore the flow rate to 1.3 mL/min at least one hour to stabilize 
the HPLC system.  
Steps xiii-xv: Data acquisition and analysis. 25 min per sample (20 min for running the 
sample and 5 min chromatographic data analysis 
 
Option C: Pyridoxal phosphate analysis 
Steps i-vii: Standard, control and sample preparation. 40 min. 
Steps viii-xvii: HPLC-FD setup: 2 hours (30 minutes to prepare the HPLC system and 
1.5 hours to equilibrate the system) . 
Steps xviii-xx: Data acquisition and analysis: 30 min per sample: 25 min for running the 
sample and 5 min for chromatographic data analysis. 
 
 
TROUBLESHOOTING 
ED performance problems HPLC coulometric ED is a high sensitivity procedure since 
the analysed compounds are expected to be 100% oxidized. Analytical troubles may be 
remarkable if ED cell cleaning and maintenance protocols are not strictly followed-up. 
In the procedures described in this protocol, the most common performance problems 
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are usually caused by the ED and not by the HPLC separation procedures. These issues 
usually occur when the ion pair agent and the pH values are strictly controlled. 
Dissolved gases and electroactive compound adsorption to the porous graphite 
electrode, the presence of electroactive compounds in the mobile phase or sample, or 
poor electrode maintenance can lead to low electrochemical signals and unacceptably 
high background currents with a noisy baseline (as described in Coulochem II. 
Operating Manual ESA Inc (USA, 1997)). When the ED is flushed with water-
methanol-water (a described in Box 1), the analytical performance remarkably 
improves. This cleaning procedure is easy to perform and consist on flush the cells with 
water during 30 minutes (4 mL/min), then 30 minutes with methanol (4 mL/min) and 
finally 30 minutes with water (4 mL/min). It is especially useful as a first procedure to 
be done when the ED analytical parameters are not good. If the ED cell does not work 
properly, refer to Table 4 for complete troubleshooting information. Additional 
troubleshooting information for the rest of the procedures can also be found in Table 4.  
 
 
ANTICIPATED RESULTS 
The procedures described in this protocol will provide suitable methods to determine 
the concentration of monoamines and their cofactors (the pterins and PLP) in CSF 
samples. 
Typical chromatograms of human CSF monoamines, are shown together with those for 
the calibration mixtures in Figure 4. A rapid identification of primary genetic or 
secondary conditions that lead to dopamine and serotonin disturbances is expected, as 
previously reported4. Four additional chromatograms depicting the neopterin, BH4, and 
BH2 (Figure 5) results in calibration mixtures and human CSF samples are shown. A 
chromatogram displaying the PLP calibration and a human CSF sample for the PLP 
analysis is also presented (Figure 6).  
An experiment that required troubleshooting to improve their analytical qualities is 
presented in Figure 7.   
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BOX 1 Electrochemical cell cleaning procedure 
Disconnect the cell from the control module and from the HPLC system.  
Flush the cell using a flushing syringe with the solutions indicated below (5-10 mL of 
each). 
1) For general cleaning, flush with deionized water/methanol/deionized water (up 
to pH > 5).  
2) For lipophilic materials, flush with deionized 
water/methanol/acetonitrile/THF/acetonitrile/methanol/deionized water.  
!CAUTION: NaOH, organic solvents and nitric acid can cause personal injury. 
Use eye protection and protective clothing in a fume hood.  
3) For organic materials, flush the system with deionized water/DMSO/deionized 
water.  
4) Silica from the column is flushed with deionized water/2 M NaOH (leave in cell 
for 10-30 minutes)/deionized water (until pH < 7).  
5) Oxidation/reduction cycle cleaning. Replace the mobile phase with fresh 
phosphate buffer 50 mM pH=3 flowing at 1 mL/minute. Apply a potential of 
+1000 mV to the electrode for 10 minutes with phosphate buffer flowing. Do 
not recycle the phosphate buffer during the treatment. After that apply a 
potential of -400 mV for 10 minutes and then apply again a potential of +1000 
mV for 30 minutes. Reset the potentials to the assay’s working potentials and 
test the response.  
6) If these procedures do not work, clean the cell with nitric acid as a last resort. 
Deionized water/6 M nitric acid (leave in the cell for 15-30 minutes)/flush the 
cell with deionized water until pH > 5. After this procedure it will be necessary 
to determine the optimum oxidation potential of the compounds of interest by 
obtaining a new hydrodynamic voltammogram.  
- End of BOX 1 -  
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TABLES 
Table 1: Overview of the procedures described in this Protocol 
 
 CSF marker Approach Option (steps) 
Biogenic amines 3-OMD HPLC-ED A (steps i and ii) 
MHPG HPLC-ED A (steps i and ii) 
5-HTP HPLC-ED A (steps i and ii) 
5HIAA HPLC-ED A (steps i and ii) 
HVA HPLC-ED A (steps i and ii) 
Pterins NP HPLC-ED-FD B (steps i and ii) 
BH2 HPLC-ED-FD B (steps i and ii) 
BH4 HPLC-ED-FD B (steps i and ii) 
Pyridoxal phosphate PLP HPLC-FD C (steps i and ii) 
 
 
 
Table 2. Summary of the equipment description and setup. HPLC systems are 
coupled to ED and FL detectors. 
Parameters  Monoamines 
Option A 
Pterins,        
Option B 
PLP,              
Option C 
Detector type  Electrochemical 
(ESA) 
Electrochemical 
(ESA)  
Fluorescence 
(Jasco) 
Fluorescence 
(Waters) 
Electrochemical 
detector 
conditions 
E1 +50 mV + 200 mV  
E2 +450 mV  - 500 mV  
Gain 200 nA 1 µA  
Filter 10 sec 10 sec  
Output +1 V -1 V  
Offset 10% 0%  
Conditioning cell potential  +1100 mV  
Fluorescence 
detector 
conditions 
Excitation  360 nm 325 nm 
Emission  440 nm 418 nm 
Gain  1 1 
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EUFS  1000 1000 
Column Stationary phase ODS (C-18) ODS (C-18)  OS (C-8)  
Large and 
diameter  
250 × 5 mm 250 x 4.6 mm  250 × 4.6 mm 
Particle size 5-µm 5-µm 5-µm 
Flow-rate (mL/min) 1.3 1.3 1.5 
Sample injection volume (µl) 30 50 50 
Pump program  Isocratic Isocratic Isocratic 
Running time (min) 30 20 25 
Column wash 1 Solvent 
 
Flow-rate, time 
Water/methanol  
92.5/7.5 (vol/vol) 
1 mL/min, 2 h 
Water/methanol  
50/50 (vol/vol), 
1 mL/min, 2 h  
Water/acetonitrile 
90/10 (vol/vol), 
1 mL/min 1 h 
Column wash 2 Solvent 
Flow-rate, time 
 Water,  
1 mL/min, 2 h 
 
Column storage Water/methanol  
80/20 (vol/vol) 
Water/methanol  
50/50 (vol/vol) 
Water/acetonitrile  
80/20 (vol/vol) 
 
 
 
Table 3. Pre-analytical protocol for CSF sample collection, management and 
storage. 
 
Tube volum Biomarkers analysed 
1st tube 5-10 drops (200-400 µL) Glucose, proteins, cells and lactate 
2nd tube 10 drops Monoamines and PLP/other vitamins 
3rd tube * 10 drops Pterins 
4th tube 10 drops Amino acids 
*The sample must be collected into a microcentrifuge tube with the following 
antioxidants: dithioerythritol (1 mg) and diethylenetriaminpentaacetic acid (1 mg). 
 
 
 
 
 
29 
 
Table 4. Troubleshooting, causes and solutions for a reliable ED and FL detection 
performance.  
*Columns should stand under mobile phase pH values beween 2.5 – 7.5.  
 
OPTION (STEP) PROBLEM 
 
POSSIBLE 
REASON 
SOLUTION 
Electrochemical detection 
A (step xiv)  
B (step vii ) 
 
The baseline is 
noisy 
There is 
dissolved gas in 
the pump head 
Degas the mobile phase (under 
helium) and re-prime the pump. 
A (step xvii )  
B (step x) 
 There is 
dissolved gas in 
the detector cell 
Remove the cell from the system, 
increase the flow rate for 30 
minutes with water/degassed 
methanol/water (4 ml/min). 
A (step xi )  
B (step vi ) 
 
 The pump head 
or system leaks 
Check the system for leakage. 
A (step xiv )  
B (step vii ) 
 The mobile phase 
is not properly 
mixed or 
degassed 
Check the aspect and degas under 
helium current. 
A (step x ) 
B (step v ) 
 Contaminants 
eluting from 
column 
Remove the column from the 
system and check if the problem 
persists. 
A and B  Electronic 
problems 
Contact maintenance service 
A (step xvii )  
B (step x ) 
High 
background 
currents 
There are 
electroactive 
impurities in the 
mobile phase 
Attach the 2 in-line electrodes to 
the same potential. If the current 
for E1 is higher than that for E2, 
mobile phase impurities are likely. 
In that case replace the mobile 
phase. 
A (step x )  
B (step v ) 
 Electroactive 
species eluted 
from the column 
Replace the column. For new 
columns, allow equilibration with 
the mobile phase, removing the ED 
to avoid silica precipitation in the 
cell. 
A (step xvii )   
B (step x ) 
 Adsorption of 
impurities onto 
electrode that 
cause decreased 
current and 
increased noise 
Reverse the potential or clean the 
cell (Box 1). 
A (step xi )   Leaking cell Check for leaks. Tighten fittings or 
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B (step vi ) replace cell. 
A (step viii ) 
B (step iii ) 
Increased back 
pressure 
Accumulation of 
particles from the 
mobile phase or 
injected samples 
Replace graphite filter. Use freshly 
prepared and filtered mobile phase 
and samples. 
A (step viii 
and/or x ) 
B (step iii and/or 
v ) 
 Accumulation of 
particles from 
column 
Replace graphite filter. Replace 
column. Be careful with silica 
columns with mobile phase pH 
values >7.5 or < 2.5. 
A and B  Clogged cell Clean the cell (see Box 1). 
A (step xvii ) 
B (step x ) 
Loss of ED cell 
response 
Unstable 
compounds 
Check stabilities of the analyzed 
biomarkers (especially 5HIAA and 
BH4).   
A (step xvii ) 
B (step (x ) 
 Decreased ED 
cell performance 
Perform hydrodynamic 
voltammogram (sigmoidal curve). 
Small variations in current may 
lead to large variations in response. 
Usually voltammogram is 
performed when the procedure is 
standardized or when the ED is 
cleaned or changed or when a 
significant loss of response is 
observed.  
A and B  Adsorption of 
impurities onto 
electrode 
Clean the cell (see Box 1) 
Fluorescence detection 
B (step x ) Noisy baseline, 
decreased 
sample energy 
levels or 
calibration 
failure 
Dirty flow cell Flush the flow cell with ultrapure 
water/6 N nitric acid/ultrapure 
water (until pH > 5). 
If this does not work you should 
replace the cell. 
B (step x )  
C (step xvi ) 
Failure to ignite 
at startup, a 
decrease in 
sensitivity or 
noisy baseline 
Damaged lamp Replace the lamp. 
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FIGURE LEGENDS 
Figure 1. Chromatograms with different monoamine related molecules (standadrd 
mixture).   
A) Upper panel (condition 1) shows a chromatogram with seven dopamine and 
serotonin compounds (L-dopa, nor-epinephrine, epinephrine, DOPAC, dopamine, 3-
metoxytyramine and serotonin). Down panel (condition 2) shows a chromatogram with 
six dopamine and serotonin compounds (DOPAC, dopamine, 5HIAA, HVA, 3-
metoxytyramine and serotonin).  Condition 1. The mobile phase is already explained in 
this protocol (Reagent Setup section). It consists in 75 mL methanol (7.5%), 13.61 
sodium acetate trihidratate, 9.60 g citric acid monohidratate, 0.44 g EDTA sodium, 
0.242 octanoilsulfonic acid and H2O up to 1 litre. Final pH= 4.00. Injection volum= 
30µL. Voltage: E1=50 mV and E2= 450 mV. Flow rate: 1.3mL per minute. The order 
of the calibrators is L-dopa, nor-epinephrine, epinephrine, DOPAC, dopamine, 3-
metoxytyramine and serotonin. Condition 2. The mobile phase consists in 320 mL 
methanol (16%), 5.44 g sodium acetate trihidratate (20 mM), 5.25 g citric acid 
monohidratate (12.5 mM), 0.074 g EDTA sodium (0.1 mM), 0.95 g octanoilsulfonic 
acid (2.2 mM) and H20 up to 2 litres. Final pH= 3.92. Injection volum= 50 µL. Voltage: 
E1=20 mV and E2=400 mV. Flow rate: 1.5mL per minute.  
 
B) Chemical structures of the molecules in panel A.  
 
Figure 2. Hydrodynamic voltammogram for 5HIAA and HVA in CSF. A 
current/voltage plot is generated after injecting a constant sample volume, which is 
measured after fixing different potentials. The lowest current that produces the highest 
analytical response to the electrode should be chosen.   
 
Figure 3. A representation of a column, the in-line graphite filter, and two in-line 
electrochemical detector cells: A) the first one is the analytical cell, which contains 
electrodes E1 and E2 (the latter is the electrochemical detector). After the sample exits 
the electrochemical detector cell and is electrochemically detected, it can be oxidized at 
the conditioning cell for fluorescence detection of neopterin and BH2. 
 
Figure 4. Chromatograms of monoamines from standard mixture and CSF 
samples from pediatric patients  
A) A calibration mixture. The elution order is 3-OMD, MHPG, 5-OHtrp, 5HIAA and 
HVA. B) CSF sample from 1-month-old patient with increased 3-OMD values. C) CSF 
sample from a 6-years-old patient. B and C show a high response in the first 2-4 
minutes of the chromatogram due to the presence of interfering compounds in the CSF 
sample. D) Chemical structures of the molecules 
 
Figure 5. Chromatograms of pterins from standard mixture and CSF samples 
from pediatric patients.  
32 
 
Representative chromatograms of BH4, neopterin and BH2 in the standard mixture and 
in a human CSF sample are presented. A) Fluorescence detection: Neopterin and BH2 
chromatograms from standard mixture (left panel) and from a human CSF sample (right 
panel). The elution order is neopterin and BH2. B) Electrochemical detection: BH4 from 
standard mixture (left panel) and from a human CSF sample (right panel). 
 
Figure 6. Chromatograms of Pyridoxal phosphate from standard mixture and CSF 
samples from pediatric patients.  
 A) Representative chromatograms of pyridoxal phospate plasma-matrix standard 
provided by Teknokroma and B) Pyridoxal phospate in a human CSF sample. The 
chemical structure drawn is the derivatized compound.  
  
Figure 7. Experiment that requires troubleshooting to improve their analytical 
quality. For HPLC-ED, the most common problems usually arise from electrochemical 
cell contamination or adsorption of electroactive impurities caused by dissolved gases in 
the system, pump problems, leaks, mobile phase not properly mixed or contaminants 
leaving from the column. Flushing the cells with water-methanol-water, as detailed in 
Box 1, is a useful practice when the baseline deviation is higher than 10%. A 
chromatogram depicting a bad performance is shown in panel A. The result after the ED 
cell cleaning procedure is shown in panel B.  
 
 
Supplementary Figure 1: Metabolic pathways for the synthesis and catabolism of 
monoamines, pterins and pyridoxal phosphate. The key metabolites for 
neurotransmitters and pterins are marked in bold and capital letters. Enzymes appear in 
italics. Tyrosine and tryptophan are the amino acid precursors of dopamine and 
serotonin, respectively. After a common rate-limiting enzymatic step, catalysed by two 
tetrahydrobiopterin (BH4)-dependent hydroxylases, L-dopa and 5-hydroxytryptophan 
are synthesized. After a common decarboxylation step, catalysed by L-aromatic amino 
acid decarboxylase (whose cofactor is pyridoxal-phosphate), the active 
neurotransmitters—dopamine and serotonin—are formed. Finally, several catabolic 
steps lead to the generation of the main end-stable metabolites, homovanillic acid 
(HVA) and 5-hydroxyindoleacetic (5HIAA) acid, which are the most useful diagnostic 
biomarkers. *Modified from Batllori et al 201629. 
Abbreviations  
AADC: aromatic L-amino acid decarboxylase; 7,8-BH2: 7,8-dihydrobiopterin; BH4: 
tetrahydrobiopterin; COMT: catechol O-methyltransferase; CR: carbonyl reductase; 
DHFR: dihydrofolate reductase; DHPR: dihydropteridine reductase; DβH: dopamine 
betahydroxylase; GABA: Gamma-aminobutyric acid; GABA-T: Gamma-
aminobutyric acid-transaminase; GAD: glutamate decarboxylase; GHB: 4-
hydroxybutyric; GTP: guanosine triphosphate; Gln: glutamine; Glu: glutamate; 
GTPCH: GTP cyclohydrolase I; 5HIAA: 5-hydroxyindoleacetic acid; 5HTP: 5-
hydroxytryptophan; 5-MTHF:  5-methyltetrahydrofolate; HCys: homocysteine; HVA: 
homovanillic acid; L-dopa: 3,4-dihydroxyphenylalanine; MAO: monoamine oxidase; 
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Met: metionine; MHPG: 3-methoxy-4-hydroxyphenylglycol; n.e.: non-enzymatic; 
3OMD: 3-O-methyldopa; OH-BH4: hydroxy-tetrahydrobiopterin; PCD: pterin-4a-
carbinolamine dehydratase; PLK: pyridoxl kinase; PLP: pyridoxal phosphate; PNMT: 
phenylethanolamine N-methyltransferase; PNPO: pyridoxine-5'-phosphate oxidase; 
PTPS: 6-pyruvoyl-tetrahydropterin synthase; q-BH2: quinoide-dihydrobiopterin; 
SAH: S-adenosylhomocysteine; SAM: S-adenosylmethionine; SR: seapiapterin 
reductase; SSADH: succinic semialdehyde dehydrogenase; TCA: tricarboxylic acid 
cicle; TPH: tryprophan-5-hydroxylase; TH: tyrosine 3-hydroxylase; VLA: vanillactic 
acid; VMA: vanillmandelic acid; vB6: vitamin B6.  
 
 
Supplementary Table 1: Cerebrospinal fluid biomarkers, associated diseases and their 
expected biochemical profile in the different biological fluids. Thirteen genetic 
disorders affecting monoamine, pterin and pyridoxal-phosphate metabolism have been 
recognized. A great variety of other neurological and environmental conditions may 
affect the status of these biomarkers. 
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